105184-38-1

Basic information

• Product Name: 3,5-Difluorophenylacetic acid
• Synonyms: 3,5-DIFLUOROPHENYLACETIC ACID;2-(3,5-DIFLUOROPHENYL)ACETIC ACID;RARECHEM AL BO 0631;TIMTEC-BB SBB006660;3,5-Difluorophenylacetic acid 99%;3,5-Difluorophenylaceticacid99%;3,5-Difluorophenylac;3,5-Difluorobenzeneaceticacid
• CAS NO: 105184-38-1
• Molecular Formula: C₈H₆F₂O₂
• Molecular Weight: 172.13
• EINECS: -0
• Product Categories: Phenylacetic acid series;Aromatic Phenylacetic Acids and Derivatives;Phenylacetic acid;Miscellaneous;C8;Carbonyl Compounds;Carboxylic Acids;Fluorine series;Pyridines ,Heterocyclic Acids
• Mol File: 105184-38-1.mol

Chemical Properties

• Melting Point: 68-70 °C(lit.)
• Boiling Point: 219°C (rough estimate)
• Flash Point: 102 °C
• Appearance: white solid
• Density: 1.3010 (estimate)
• Vapor Pressure: 0.0241mmHg at 25°C
• Refractive Index: 1.57
• Storage Temp.: Sealed in dry,Room Temperature
• Solubility: soluble in Methanol
• PKA: 3.90±0.10(Predicted)
• BRN: 3605064
• CAS DataBase Reference: 3,5-Difluorophenylacetic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 3,5-Difluorophenylacetic acid(105184-38-1)
• EPA Substance Registry System: 3,5-Difluorophenylacetic acid(105184-38-1)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36-36/37/39-22-22/26/36/37/39
• WGK Germany: 3
• HazardClass: IRRITANT
• Hazardous Substances Data: 105184-38-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
3,5-Difluorophenylacetic acid is used as a key intermediate in the synthesis of various pharmaceutical compounds. Its unique structure allows for the development of new drugs with improved potency and selectivity.
Used in Biological Research:
3,5-Difluorophenylacetic acid is used as a research tool in the study of the inhibition of penicillin biosynthetic enzymes by phenylacetic acid halogen derivatives. This helps in understanding the mechanisms of action and potential applications in antibiotic development.
Used in Cancer Research:
3,5-Difluorophenylacetic acid is used in the preparation and in vitro cytotoxic activities of sorafenib derivatives. Sorafenib is a kinase inhibitor used in the treatment of various cancers, and the study of its derivatives can lead to the discovery of more effective anticancer agents.
Used in Peptide Synthesis:
3,5-Difluorophenylacetic acid is used in the synthesis of N-[N-(3,5-difluorophenylacetyl)-L-alanyl]-L-phenylglycine tert-butyl ester and N-acylalanine. These compounds have potential applications in the development of novel peptide-based drugs and therapeutic agents.

InChI:InChI=1/C7H5F3IN/c8-7(9,10)4-1-2-5(11)6(12)3-4/h1-3H,12H2

Upstream product

• 210530-70-4 methyl 2-(3,5-difluorophenyl)acetate 
• 124-38-9 carbon dioxide 
• 163733-96-8 3,4,5-trifluoro aniline 
• 372-38-3 1,3,5-trifluorobenzene 

Downstream Products

• 139368-37-9 ethyl 2-(3,5-difluorophenyl)acetate 
• 127035-82-9 4-[(E)-2-(3,5-Difluoro-phenyl)-vinyl]-2,6-dimethyl-phenol 
• 157033-24-4 3,5-difluorophenylacetyl chloride 
• 208255-34-9 (S)-2-{(S)-2-[2-(3,5-Difluoro-phenyl)-acetylamino]-propionylamino}-3-phenyl-propionic acid methyl ester 
• 208255-51-0 N-[N-3,5-difluorophenylacetyl]-1-alanyl-(S)-phenylglycine methyl ester 
• 208254-41-5 N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-(S)-2-aminohexanoate methyl ester 
• 208255-55-4 N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-(S)-2-amino-3-cyclohexylpropionate methyl ester 
• 467223-90-1 2-(3,5-difluorophenyl)ethan-1-ol 
• 208255-80-5 ((S)-tert-butyl 2-((S)-2-(2-(3,5-difluorophenyl)acetamido)propanamido)-2-phenylacetate) 
• 683277-97-6 N-(2-benzyloxy-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl)-2-[2-(3,5-difluoro-phenyl)-acetylamino]-propionamide 

Relevant articles and documents

Desulfonylative Electrocarboxylation with Carbon Dioxide

Electrocarboxylation of organic halides is one of the most investigated electrochemical approaches for converting thermodynamically inert carbon dioxide (CO2) into value-added carboxylic acids. By converting organic halides into their sulfone derivatives, we have developed a highly efficient electrochemical desulfonylative carboxylation protocol. Such a strategy takes advantage of CO2as the abundant C1 building block for the facile preparation of multifunctionalized carboxylic acids, including the nonsteroidal anti-inflammatory drug ibuprofen, under mild reaction conditions.

Diphenylurea derivatives for combating methicillin- and vancomycin-resistant Staphylococcus aureus

A new class of diphenylurea was identified as a novel antibacterial scaffold with an antibacterial spectrum that includes highly resistant staphylococcal isolates, namely methicillin- and vancomycin-resistant Staphylococcus aureus (MRSA & VRSA). Starting with a lead compound 3 that carries an aminoguanidine functionality from one side and a n-butyl moiety on the other ring, several analogues were prepared. Considering the pharmacokinetic parameters as a key factor in structural optimization, the structure-activity-relationships (SARs) at the lipophilic side chain were rigorously examined leading to the discovery of the cycloheptyloxyl analogue 21n as a potential drug-candidate. This compound has several notable advantages over vancomycin and linezolid including rapid killing kinetics against MRSA and the ability to target and reduce the burden of MRSA harboring inside immune cells (macrophages). Furthermore, the potent anti-MRSA activity of 21n was confirmed in?vivo using a Caenorhabditis elegans animal model. The present study provides a foundation for further development of diphenylurea compounds as potential therapeutic agents to address the burgeoning challenge of bacterial resistance to antibiotics.

Preparation method of fluorophenylacetic acid

The invention relates to the field of chemical synthesis, and particularly relates to a preparation method of fluorophenylacetic acid. The invention provides a preparation method of fluorophenylacetic acid. The preparation method comprises the following steps: diazotization addition reaction: enabling a compound of the formula II to react in a system containing vinylidene chloride, acid, a diazonino reagent, a phase transfer catalyst and a copper catalyst to produce a compound of the formula III; and hydrolysis reaction: hydrolyzing the compound of the formula III to produce a compound of the formula I under the existence condition of acid. The preparation method is simply and easily available in raw materials, simple and convenient to operate, low in raw material cost, mild in reaction conditions, and low in danger, free from the use of high-price noble metal catalyst and complicated industrial operation means, and the quality of the product is stable, and therefore, the preparation method is suitable for industrial large-scale production.

Synthesis of dihalophenylacetic acids using aromatic nucleophilic substitution strategy

A simple synthetic strategy to dihalophenylacetic acids and specifically 3,5-difluorophenylacetic acid an important pharmaceutical intermediate was developed. The aromatic nucleophilic substitution of dihalofluorobenzenes using the anion of ethyl cyanoacetate yielded ethyl dihalophenylcyanoacetates. The basic decarboxylation of the ethyl dihalophenylcyanoacetates produced targeted dihalophenylacetic acids.